Adma Biologics | ADMA - 税前利润

金融业

USD

USD 665.18M

现金及等价物

USD 138.15M

USD 50.4M

USD 511.17M

USD 73.54M

USD 83.12M

USD 62.75M

USD 73.59M

624

EPS每股收益

USD 0.19

股本和储备

USD 390.33M

USD 88.82M

债务利息支出

USD 1.63M

USD 376K

USD 193.58M

USD 2.01B

USD 49.38M

USD 76.41M

USD 62.75M

普通股股本

USD 237.88M

29.73

USD 61.59M

USD 114.5M

销售和管理费用

USD 20.19M

USD 222.1M

贸易债权人

USD 20.52M

应收帐款人

USD 158.43M

	税前利润	更改		日
Adma Biologics	USD 61.59M		14.07M	2025-12
Alnylam Pharmaceuticals	USD 221.65M		60.52M	2026-03
BioCryst Pharmaceuticals	USD 248.02M		235.89M	2025-12
Minerva Neurosciences	USD 22.51M		30.74M	2024-09
Novavax	USD 17.9M		220.94M	2025-12
Omeros	USD -65.12M		21.27M	2024-06
Takeda	JPY -52.48B		186.34B	2026-03